Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: A European Innovative Therapies for Children.

Slides:

Advertisements

Similar presentations

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.

Advertisements

EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep

Evaluation of survival across several treatment lines in metastatic colorectal cancer: Analysis of the FIRE-3 trial (AIO KRK0306) D.P. Modest, I. Ricard,

Pre- and per-treatment 18F-FDG PET/CT parameters to predict recurrence and survival in cervical cancer Julie Leseur, Geoffrey Roman-Jimenez, Anne Devillers,

Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase.

European Journal of Cancer

Nicoletta Colombo, Martin Gore

Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST) Axel.

Rare cancers of the head and neck area in Europe

Volume 144, Issue 1, Pages (January 2017)

Volume 164, Issue 6, Pages (December 2000)

Prostate cancer mortality in screen and clinically detected prostate cancer: Estimating the screening benefit Pim J. van Leeuwen, David Connolly, Anna.

Whole brain radiotherapy plus stereotactic radiosurgery (WBRT+SRS) versus surgery plus whole brain radiotherapy (OP+WBRT) for 1–3 brain metastases: Results.

Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancer Philippe O. Gannon, Laurent Lessard, Louis-Mathieu.

Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial) M. Yoshida, K. Muro, A. Tsuji,

Lactobacillus brevis CD2 lozenges reduce radiation- and chemotherapy-induced mucositis in patients with head and neck cancer: A randomized double-blind.

Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without.

Colour contrast in ballistic gelatine

Fibrolamellar variant of hepatocellular carcinoma does not have a better survival than conventional hepatocellular carcinoma – Results and treatment recommendations.

Amy M. Lin, Charles J. Ryan, Eric J. Small

A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease Yoshihiro Kobashi,

Volume 32, Issue 1, Pages (February 2013)

The efficacy of Chinese herbal medicine as an adjunctive therapy for colorectal cancer: A systematic review and meta-analysis Linda L.D. Zhong, Hai-Yong.

The effect of perioperative chemotherapy for patients with an adenocarcinoma of the gastroesophageal junction: A propensity score matched analysis K.

Endemic fungal infections caused by Cryptococcus neoformans and Penicillium marneffei in patients infected with human immunodeficiency virus and treated.

Brain stimulation as a neuromodulatory epilepsy therapy

Building better therapy for children with acute lymphoblastic leukemia

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria M. Tazdait,

Treatment of Advanced and Metastatic Renal Cancer: A Revolution?

Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI Alix O’Meara, Jörg Halter, Dominik.

Cortical stimulation parameters for functional mapping

Volume 10, Issue 6, Pages (June 2009)

A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma Isabelle Opitz, MD, Martina Friess,

Comparative Effectiveness Research

Early Response to Platinum-Based First-Line Chemotherapy in Non-small Cell Lung Cancer May Predict Survival Bhawna Sirohi, MBBS, DCH, Sue Ashley, BSc,

Targeting T Cell Co-receptors for Cancer Therapy

Volume 10, Issue 5, Pages (November 2005)

Response to Carfilzomib Therapy

Endemic fungal infections caused by Cryptococcus neoformans and Penicillium marneffei in patients infected with human immunodeficiency virus and treated.

Axillary radiotherapy for nodal lymphoma: What CTV expansion is required to account for absence of pre-chemotherapy treatment position FDG PET-CT? Robin.

Thymoma: A Population-Based Study of the Management and Outcomes for the Province of British Columbia Caroline Mariano, MD, Diana N. Ionescu, MD, Winson.

Simultaneous integrated prophylactic cranial irradiation in sino-nasal cancer Kenneth Jensen, Maja Bendtsen Sharma, Simon Lenler-Eriksen, Per Friis, Anne.

Vitaly A. Kushnir, Jennifer Choi, Sarah K. Darmon, David F

Phase 2 Study of Pemetrexed and Itraconazole as Second-Line Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer Charles M. Rudin, MD, PhD,

Ahmadi T et al. Proc ASH 2011;Abstract 266.

Hepatology may have problems with putative surrogate outcome measures

Feasibility of stereotactic body radiotherapy for locally-advanced non-small cell lung cancer Katrina Woodford, Vanessa Panettieri, Trieumy Tran Le,

(A) Survival time. (A) Survival time. All patients. (a) PFS since the start of EGFR-TKI (groups A, B and C). (b) OS since the start of EGFR-TKI (groups.

Contamination when collecting trace evidence—An issue more relevant than ever? Ines Pickrahn, Gabriele Kreindl, Eva Müller, Bettina Dunkelmann, Waltraud.

Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter.

Evaluation of Antitumor Activity Using Change in Tumor Size of the Survivin Antisense Oligonucleotide LY in Combination with Docetaxel for Second-Line.

Arlene Chan, Marc Buyse, Bin Yao The Lancet Oncology

Cumulative success rates following mild IVF in unselected infertile patients: a 3-year, single-centre cohort study Daniel Bodri, Satoshi Kawachiya, Michaël.

Is an increased drop-in rate appropriate with enhanced DNA profiling?

The posterior cerebellum, a new organ at risk?

An interstitial hypothesis for breast cancer related lymphoedema

Sites of recurrent disease and prognostic factors in SCLC patients treated with radiochemotherapy Rebecca Bütof, Calogero Gumina, Chiara Valentini, Antje.

Abstracts Clinical Microbiology and Infection

Maxim Grymonprez, Vincent Vakaet, Maryam Kavousi, Bruno H. Stricker, M

Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,

Colombian results of the interlaboratory quality control exercise 2015

The clinical significance of indeterminate pulmonary nodules in melanoma patients at baseline and during follow-up chest CT Magdy Soliman, Teresa Petrella,

KRAS Mutations in Advanced Nonsquamous Non–Small-Cell Lung Cancer Patients Treated with First-Line Platinum-Based Chemotherapy Have No Predictive Value

Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.

PARAMOUNT: Descriptive Subgroup Analyses of Final Overall Survival for the Phase III Study of Maintenance Pemetrexed versus Placebo Following Induction.

Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line.

(A) Survival curves according to clinical response.

Randomized Phase II Study of Maintenance Irinotecan Therapy Versus Observation Following Induction Chemotherapy with Irinotecan and Cisplatin in Extensive.

Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non- small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339)

Survival, subsequent therapies, and response.

Presentation transcript:

Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: A European Innovative Therapies for Children with Cancer- SIOP-European Neuroblastoma study Angela Di Giannatale, Nathalie Dias-Gastellier, Annick Devos, Kieran Mc Hugh, Ariane Boubaker, Frederic Courbon, Arnaud Verschuur, Stéphane Ducassoul, Katty Malekzadeh, Michela Casanova, Loredana Amoroso, Pascal Chastagner, Christian M. Zwaan, Caroline Munzer, Isabelle Aerts, Judith Landman-Parker, Riccardo Riccardi, Marie-Cecile Le Deley, Birgit Geoerger, Hervé Rubie European Journal of Cancer Volume 50, Issue 1, Pages 170-177 (January 2014) DOI: 10.1016/j.ejca.2013.08.012 Copyright © 2013 Elsevier Ltd Terms and Conditions

Fig. 1 Patient’s response at Cycle 2 and best response in all 38 treated and for response evaluable patients. ∗Stop Treatment after one cycle for toxicity; ∗∗Clinical PD after one cycle; CR: complete response; PR: partial response; MR: mixed response; SD: stable disease; PD: progression disease. European Journal of Cancer 2014 50, 170-177DOI: (10.1016/j.ejca.2013.08.012) Copyright © 2013 Elsevier Ltd Terms and Conditions

Fig. 2 Progression-free survival (A) and Overall survival (B) in all 38 patients included and treated with topotecan–temozolomide (TOTEM) combination as compared to 25 patients treated with temozolomide alone. Graphs are estimated using Kaplan–Meier method and represent data from the here presented 38 patients treated with TOTEM combination (red) and 25 patients treated with Temozolomide alone (blue) reported by Rubie et al. [10]. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) European Journal of Cancer 2014 50, 170-177DOI: (10.1016/j.ejca.2013.08.012) Copyright © 2013 Elsevier Ltd Terms and Conditions